Chairman of the Board of Directors, Vedanta Biosciences
Christopher Viehbacher is a member of the Board of PureTech Ventures and the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 biopharmaceutical company with a market capitalization of over $100 billion. During Viehbacher’s six year tenure, Sanofi underwent a significant business transformation, completing over $30 billion of acquisitions, most notably that of Genzyme. Viehbacher was also the Chairman of the Board of Genzyme in Boston. Prior to joining Sanofi, Viehbacher spent 20 years with GlaxoSmithKline ultimately as President of GSK’s North American pharmaceutical division. Viehbacher was a Member of the Board of Directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. Viehbacher began his career with Price Waterhouse Coopers and qualified as a Chartered Accountant.
Viehbacher has co-chaired the CEO Roundtable on Neglected Diseases with Bill Gates, which led to over 1.3 billion people being treated for such diseases free of charge and he continues to chair the CEO Roundtable on Cancer. He was the Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as President of the European Federation of Pharmaceutical Industries and Associations. At the World Economic Forum at Davos, Viehbacher was a Chair of the Health Governors and co-chaired an initiative to create a Global Charter for Healthy Living. He was also a member of the International Business Council.
Viehbacher has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France’s highest civilian honor, the Léegion d’Honneur. Various awards from the Thompson Reuters/Extel Investor Survey, including top CEO and top European Company, have recognized his commitment to investor relations.